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Currently, this treatment option is only available in a small
number of centres worldwide and only at our unit in the
UK. Increasing interest suggests that in future more anaes-
thetists may be asked to provide anaesthesia for patients
receiving intralesional bleomycin treatment.
Bleomycin chemotherapy is a recognized cause of pul-
monary pathology.3 The risk of developing bleomycin-
related pulmonary injury is known to be increased by
alveolar hyperoxia even in cases where there has been an
interval of 6–12 months between bleomycin exposure and
hyperoxic anaesthesia.4 Animal studies have shown that
the risk of developing bleomycin-related pulmonary path-
ology is increased if bleomycin is administered concur-
rently with the alveolar hyperoxia.5 6 This has implications
for the anaesthetic management of our patients where,
despite a lower dose of bleomycin required than that used
in chemotherapy, the drug is administered during general
anaesthesia.
In our unit, we use the following protocol. Before
admission, adult patients are referred to a respiratory phys-
ician for assessment by history, examination, baseline
spirometry, transfer factor (DLCO), and a chest radio-
graph. Children are assessed by a paediatrician with a
special interest in respiratory disease; baseline respiratory
function tests being obtained where possible. Patients are
reviewed by the respiratory team midway through a course
of treatments and after completion of treatment.
The aim is to provide safe anaesthesia while avoiding
alveolar hyperoxia. Pre-oxygenation is avoided and sup-
plemental oxygen is restricted, aiming for a normal end-
tidal oxygen concentration and a target minimum SaO2 of
94%. Ventilation is assisted to prevent hypoxaemia result-
ing from alveolar hypoventilation. Most cases can be
managed with a laryngeal mask airway or oropharyngeal
airway, thus avoiding any desaturation associated with
extubation. The procedure is performed in the anaesthetic
room to avoid hypoxic events upon transfer into theatre. If
difficulties arise, the anaesthetist is encouraged to use
oxygen supplementation as necessary until problems are
resolved. Before transfer to recovery, the patient should
have resumed satisfactory spontaneous respiration on air.
During recovery, no supplemental oxygen is prescribed
unless the oxygen saturation decreases below 94% and, if
required, the lowest effective supplementation is used.
We have reviewed our first 3 yr experience of providing
general anaesthesia for these patients. Forty-nine patients
received a total of 187 general anaesthetics. Nineteen
(42.9%) of the patients were children, with seven (14.3%)
under 1 yr old. The majority (65.3%) of procedures
involved lesions on the face; a further 12.2% involved the
head and neck. The median FIO2 during treatment was
0.21. About 66.5% of patients had an FIO2 of 0.25 or less,
86.9% had an FIO2 of 0.3 or less, and 91.7% of patients
had an FIO2 of 0.35 or below (Table 1). There were only
two (1.1%) procedures where oxygen saturation levels
below 90% were recorded. Thirty-three (17.6%)
procedures required the patient to receive oxygen in recov-
ery. There were no cases of bleomycin-related pulmonary
disease. Two patients reported bleomycin-related skin
reactions.
With careful respiratory assessment and monitoring, and
using an anaesthetic technique that attempts to avoid
alveolar hyperoxia, intralesional bleomycin therapy of vas-
cular malformations under general anaesthesia has not
been associated with the development of pulmonary com-
plications in patients treated at our unit.
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Target controlled infusion of opioids for
bariatric surgery and morphine loading dose
Editor—I read with interest the useful study by De
Baerdemaeker and colleagues,1 but wish to raise some
concerns about the paper. First, the authors did not declare
Table 1 FIO2 administered during procedure (n¼ 167)
FIO2 n %
0.21–0.25 111 66.5
0.26–0.30 34 20.4
0.31–0.35 8 4.8
0.36–0.40 3 1.8
0.41–0.45 2 1.2
0.46–0.50 8 4.8
.0.51 1 0.6
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their sample size calculation and how these 40 patients
were selected. Secondly, I am concerned that morphine
was not given i.v. in a timely fashion to aid analgesia in
post-anaesthesia care unit (PACU), as morphine peak
effect is relatively late, and I believe delaying giving these
patients (especially the remifentanil group) morphine is
unethical. Thirdly, in our hospital, we do not routinely pre-
scribe i.v. patient-controlled analgesia (PCIA) to laparo-
scopic banding patients after operation, and most patients
do well and leave hospital after their gastrographin
swallow test next morning on simple oral analgesia.
Y. Al-Tamimi
Perth, Australia
E-mail: altamimiy@ramsayhealth.com.au
Editor—We thank Dr Al-Tamimi for his comments and
his interest in our paper and for the opportunity to reply to
him. We will address his points in turn. First, details of
the sample size calculation and patient selection can be
found in our Methods section. Since the primary endpoint
of the study was the postoperative morphine consumption,
power analysis was based on a similar protocol performed
in non-obese patients.2 Group allocation was at random
with blinded envelopes.
Secondly, we would like to point out that the patients in
both study groups received acetaminophen 2 g i.v. and
diclofenac 150 mg i.v. at the beginning of surgery. Thus,
the patients in the remifentanil group received non-opioid
transitional postoperative analgesia. The initial mean (SD)
visual analogue scale (VAS) score in the remifentanil
group on admission in the PACU was 4.3 (1.7) and this
reflects suboptimal analgesia, but to our opinion not in the
range of unethical clinical practice. In non-obese patients,
most clinicians will use an intraoperative i.v. morphine
dose of 0.1–0.25 mg kg21 administered 30–60 min before
the end of surgery for the immediate postoperative analge-
sia after a remifentanil-based anaesthesia. However, there
are no clear guidelines in the literature on the safe use of
an intraoperative loading dose of morphine based on ideal
body weight (IBW) in morbidly obese patients. When
studying the influence of diurnal variation and morbid
obesity on the morphine requirements using PCIA, Graves
and colleagues3 found that morphine dosing rate (mg kg21
h21) normalized to IBW was a better predictor of analge-
sic requirements. More recent studies on the use of PCIA
with morphine in morbidly obese patients have demon-
strated its safety4 5 even in obese patients with obstructive
sleep apnoea syndrome (OSAS).6 All authors used i.v.
morphine in the PACU titrated individually in divided
doses of 2.5–5 mg with 10 min intervals to achieve an
acceptable pain score before instituting their PCA device.
Ahmad and colleagues6 used a prudent intraoperative
loading dose of 50 mg kg21 IBW morphine at the end of
the pneumoperitoneum. In our study, performed on mor-
bidly obese patients without OSAS or serious cardiopul-
monary disease, the PCIA device delivered a morphine
loading dose (0.15 mg kg21 IBW) at the moment of first
analgesic request. Our postoperative data on arterial blood
gas analysis and spirometry show the safety of this strategy
in this type of obese patients. Nevertheless, it took 2 h to
register VAS pain scores below three in both study groups.
Until we see prospective studies on the accurate timing
and safety of an intraoperative loading dose of morphine
for morbidly obese patients in the range of 0.15 mg kg21
IBW, the PCIA recommendations of Levin and col-
leagues7 still apply: no basal infusion of morphine, bolus
doses of 0.5–1.0 mg with a 10 min interval, and titration
to a desirable effect within the first few hours after
surgery. Finally, we agree with Dr Al-Tamimi that PCIA
morphine is not a routinely used postoperative analgesic
regimen for laparoscopic gastric banding. For study pur-
poses, morphine consumption was used as an objective
and quantitative measure of postoperative pain. We are
convinced that with simple oral analgesics (and infiltration
with local anaesthetics), satisfactory postoperative analge-
sia can be achieved.
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